2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | Significance | |
---|---|---|---|---|---|---|---|---|---|
Total of patients with diabetes screened | 5027 (32.65%) | 4989 (32.40%) | 5312 (34.50%) | 5367 (34.86%) | 5276 (34.22%) | 6337 (41.16%) | 5623 (36.52%) | 6125 (34.42%) | p=1.402 |
Total DR | 407 (8.09%) | 402 (8.06%) | 428 (8.06%) | 432 (8.05%) | 426 (8.07%) | 556 (8.77%) | 502 (8.92%) | 551 (8.99%) | p<0.001 |
Classification of DR | |||||||||
Mild DR | 349 (6.94%) | 344 (6.89%) | 368 (6.92%) | 377 (7.02%) | 363 (6.88%) | 441 (6.96%) | 397 (7.06%) | 432 (7.05%) | p<0.001 |
Moderate DR | 33 (0.65%) | 32 (0.64%) | 33 (0.62%) | 31 (0.58%) | 33 (0.62%) | 64 (1%) | 67 (1.14%) | 65 (1.06%) | p<0.001 |
Severe DR | 24 (0.48%) | 26 (0.52%) | 26 (0.49%) | 24 (0.48%) | 30 (0.57%) | 47 (0.74%) | 43 (0.76%) | 46 (0.75%) | p<0.001 |
Proliferative DR | 1 (0.02%) | No cases | 1 (0.02%) | No cases | No cases | 4 (0.06%) | 5 (0.08%) | 8 (0.13%) | p<0.001 |
Diabetic macular oedema (DMO) study | |||||||||
Total DMO | 104 (2.00%) | 101 (2.02%) | 112 (2.11%) | 114 (2.12%) | 110 (2.08%) | 150 (2.36%) | 135 (2.40%) | 153 (2.49%) | p<0.001 |
Extrafoveal DMO | 39 (0.75%) | 35 (0.72%) | 43 (0.84%) | 37 (0.69%) | 38 (0.72%) | 58 (0.92%) | 48 (0.86%) | 59 (0.96%) | p<0.001 |
CSMO* | 65 (1.25%) | 66 (1.25%) | 69 (1.27%) | 77 (1.43%) | 72 (1.36%) | 92 (1.44%) | 87 (1.54%) | 94 (1.53%) | p<0.001 |
Ratio CSMO/Extrafoveal DMO | 1.66 | 1.8 | 1.51 | 2.07 | 1.88 | 1.56 | 1.79 | 1.64 | p=0.142 |
The values are compared between groups using the one-way ANOVA. CSMO*, clinically significant macular oedema.